Nearly 5% of patients receiving idarucizumab for dabigatran reversal had this effect?
Pollack CV et al. reported that nearly 5% (24 patients) of patients receiving idarucizumab had thrombotic events including ischemic stroke, DVT and pulmonary embolism within 30 days of receiving idarucizumab. (Pollack CV et al. Idarucizumab for Dabigatran Reversal – Full Cohort Analysis. NEJM 2017; 377: 431-441. doi 10.1056/NEJMoa1707278)